Cargando…

Daratumumab Interferes with Allogeneic Crossmatch Impacting Immunological Assessment in Solid Organ Transplantation

We report the first case of Daratumumab interference of allogeneic crossmatch tests repeatedly causing aberrant false-positive results, which inadvertently delayed transplant for a waitlisted renal patient with multiple myeloma. Daratumumab is an IgG1κ human monoclonal antibody commonly used to trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ho, Chak-Sum, Putnam, Kyle R., Peiter, Christine R., Herczyk, Walter F., Gerlach, John A., Lu, Yee, Campagnaro, Erica L., Woodside, Kenneth J., Cusick, Matthew F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605360/ https://www.ncbi.nlm.nih.gov/pubmed/36294380 http://dx.doi.org/10.3390/jcm11206059

Ejemplares similares

Antibody Therapeutics as Interfering Agents in Flow Cytometry Crossmatch for Organ Transplantation
por: Kueht, Michael L., et al.
Publicado: (2023)

Accuracy of point‐of‐care crossmatching methods and crossmatch incompatibility in critically ill dogs
por: Marshall, Hayden, et al.
Publicado: (2020)

Implication of a positive virtual crossmatch with negative flow crossmatch: A mind-boggler
por: Chowdhry, Mohit, et al.
Publicado: (2020)

Immediate transfusion without crossmatching
por: Moriwaki, Y, et al.
Publicado: (2008)

Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab
por: Nedumcheril, Marilyn T, et al.
Publicado: (2021)

The Assessment and Outcomes of Crossmatching in Lung Transplantation in Korean Patients
por: Kim, Ha Eun, et al.
Publicado: (2022)

Improving Crossmatch Techniques and Graft Outcomes
por: Vincent, L.
Publicado: (2018)

Virtual and Reality: An Analysis of the UCLA Virtual Crossmatch Exchanges
por: Locke, Arlene F., et al.
Publicado: (2023)

Therapeutic Plasma Exchange Ameliorates Incompatible Crossmatches
por: Özen, Mehmet, et al.
Publicado: (2016)

Modified stall‐side crossmatch for transfusions in horses
por: Casenave, Pauline, et al.
Publicado: (2019)

Practical Solutions for Problems in Blood Grouping and Crossmatching
por: Andıç, Neslihan
Publicado: (2022)

Principles of Virtual Crossmatch Testing for Kidney Transplantation
por: Bhaskaran, Madhu C., et al.
Publicado: (2022)

Crossmatch: Alloimmunization versus unspecific agglutination reactions?
por: Giger, Urs
Publicado: (2023)

BSHI/BTS guidance on crossmatching before deceased donor kidney transplantation
por: Peacock, S., et al.
Publicado: (2021)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Comparison of Physical Crossmatch and Virtual Crossmatch to Identify Preexisting Donor-Specific Human Leukocyte Antigen (HLA) Antibodies and Outcome Following Kidney Transplantation
por: Peng, Bo, et al.
Publicado: (2019)

Enhanced virtual crossmatch in intestinal transplantation: association with outcomes and application in practice
por: Moon, Jang Il, et al.
Publicado: (2021)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody
por: Lin, Mei-Hwa, et al.
Publicado: (2017)

Human leukocyte antigen typing and crossmatch: A comprehensive review
por: Althaf, Mohammed Mahdi, et al.
Publicado: (2017)

Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches
por: Colmenero Velazquez, Argentina, et al.
Publicado: (2020)

Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma
por: Afrough, Aimaz, et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Phasing out the pre-transplant cytotoxicity crossmatch: Are we missing something?
por: Abud, Jamile, et al.
Publicado: (2021)

Potential serological challenges caused by anti-IH antibody in the crossmatch laboratory
por: Raturi, Manish, et al.
Publicado: (2021)

Is It Time to Switch from Conventional Coombs Crossmatching to the Type and Screen Protocol?
por: Baiju, Nithya M, et al.
Publicado: (2023)

Daratumumab for donor-specific anti-HLA antibody desensitization in a case of HLA-mismatched allogeneic stem cell transplantation
por: Ibrahim, Uroosa, et al.
Publicado: (2023)

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
por: Vaxman, I., et al.
Publicado: (2023)

Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Living donor liver transplantation using sensitized lymphocytotoxic crossmatch positive graft
por: Aoki, Taku, et al.
Publicado: (2012)

Median channel shift less than the cutoff in flow cytometric crossmatch: Not to be ignored!
por: Dorwal, Pranav, et al.
Publicado: (2017)

The CDC crossmatch in the era of flow cytometric cross-match and single antigen beads
por: Mahowald, Grace Kao
Publicado: (2021)

Reducing unnecessary crossmatching for hip fracture patients by accounting for preoperative hemoglobin concentration
por: Amin, Raj M, et al.
Publicado: (2021)

C1Q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity but Low Sensitivity When Predicting Flow Crossmatch
por: Arreola-Guerra, José M., et al.
Publicado: (2016)

Interferon α interferes with immunological tolerance
por: Becker, Christian, et al.
Publicado: (2013)

Infections and immunological hazards of allogeneic bone transplantation
por: Hofmann, G. O., et al.
Publicado: (1995)

False Positive B-Cells Crossmatch after Prior Rituximab Exposure of the Kidney Donor
por: Desoutter, Judith, et al.
Publicado: (2016)

Agreement of stall‐side and laboratory major crossmatch tests with the reference standard method in horses
por: Fenn, Melissa S., et al.
Publicado: (2020)

Critical analysis of two cases of major crossmatch incompatibility in tertiary care hospital in Delhi
por: Puri, Vandana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_19k6f6o4kj6lqfbnsjoqcdrfvp